Strengthening Healthcare Investment and Biotechnology Cooperation in Rwanda
Exon Genetic & Biotechnology continues to pursue opportunities that contribute to the development of healthcare, medical technology and biotechnology across Africa. As part of this commitment, the company’s leadership held an important meeting with Rwanda’s Deputy Minister of Health, Dr. Yvan Butera, to discuss planned healthcare investments and ongoing projects in Rwanda.
The meeting, held on July 12, 2023, brought together BEYLER GROUP Chairman of the Board Dr. Hulusi Söğütlü and Exon’s Rwanda representative Abraham Olwenyi. During the visit, the delegation provided information regarding the health investments and projects that the group planned to undertake in Rwanda.
A Focus on Healthcare Investment in Rwanda
Healthcare investment is an important component of strengthening healthcare systems and expanding access to modern medical technologies. For biotechnology and healthcare companies, collaboration with government institutions can help ensure that investment plans are aligned with national priorities and local requirements.
During the meeting, Exon and its delegation presented information about the company’s planned investments and ongoing activities in Rwanda. The discussions represented an opportunity to communicate the group’s vision and explore areas where its experience and capabilities could contribute to the healthcare sector.
According to Exon’s original report, Dr. Yvan Butera expressed satisfaction with the high-level technology investments the company planned to make and indicated that he would provide support and activate relevant units.
Helpful Advice
Quality Assurance
Reliable Experts
Building Partnerships Through Dialogue
For Exon Genetic & Biotechnology, engagement with public institutions forms an important part of its approach to international healthcare development.
The company operates across areas including laboratory diagnostic testing, medical equipment and consumables, and medical consultancy. Its stated activities include PCR test kits, rapid diagnostic tests, biochemistry tests, CBC tests, immunoassay tests and BTI production. Exon also states that it has operations and production capabilities in Uganda and Türkiye, with a focus on expanding its reach across Africa.
This broader healthcare focus provides a foundation for continued engagement with institutions and partners across the region.
Dr. Hulusi SÖĞÜTLÜ - Chairman of the Board, BEYLER GROUP
“Our goal is to establish meaningful partnerships that bring advanced healthcare technology and sustainable investment opportunities to the markets we serve. We appreciate the support and cooperation of Rwanda’s health authorities as we continue developing our planned projects in the country.”
Supporting the Future of Healthcare Technology
The Rwanda meeting demonstrates the importance of dialogue between healthcare companies and government authorities when exploring new investment opportunities.
For biotechnology companies, successful healthcare investment requires more than technology alone. It also involves understanding local healthcare priorities, regulatory requirements, infrastructure needs and the wider environment in which healthcare services are delivered.
Engagement with government stakeholders can therefore help establish a better understanding of how planned investments may fit within a country’s healthcare development objectives.
Exon Genetic & Biotechnology’s Regional Vision
Exon Genetic & Biotechnology states that its priority market is East Africa, with an ambition to expand its activities across the wider African continent. The company’s portfolio includes diagnostic testing, medical equipment and consumables, and healthcare consultancy services.
The company’s activities in Rwanda form part of this wider regional outlook.
The 2023 meeting with Rwanda’s Deputy Minister of Health therefore represents an important point in Exon and BEYLER GROUP’s engagement with Rwanda and its healthcare sector.
Looking Ahead
The meeting with Dr. Yvan Butera highlighted the importance of continued cooperation, communication and institutional engagement as Exon Genetic & Biotechnology explores healthcare investment opportunities in Rwanda.
Exon expressed its appreciation to Dr. Yvan Butera for his support and hospitality during the visit.
As healthcare systems across Africa continue to evolve, partnerships involving biotechnology, diagnostics, medical technology and healthcare services can play an important role in supporting sustainable development.
About Exon Genetic & Biotechnology
Exon Genetic & Biotechnology operates in laboratory diagnostics, medical equipment supply and healthcare consultancy. The company states that its products and activities include PCR test kits, rapid tests, biochemistry tests, CBC tests, immunoassays and BTI production. It also provides healthcare consultancy and turnkey healthcare project services.
